In the cross-sectional analysis, plasma phosphorylated-tau217 was increased in Niemann–Pick disease type C compared with controls (2.52 ± 1.93 versus 1.02 ± 0.34 pg/mL, respectively, P < 0.001) and inversely correlated with age at disease onset (R = 0.54, P < 0.001). In the ...
We measured plasma levels of tau phosphorylated at threonine 217 (P‐tau217) in the prospective Swedish BioFINDER (BF) I and II studies (n=1057). BF㊣I included cognitively unimpaired individuals (CU, n=275) and patients with mild cognitive impairment (MCI, n=161), AD dementia (n=114)...
Detection of pathological hallmarks of AD—accumulation of amyloid β (Aβ) in plaques and hyper-phosphorylated tau in neurofibrillary tangles—in vivo using Aβ and p-tau in cerebrospinal fluid (CSF) [3] or using amyloid/tau-Positron Emission Tomography (PET) [4]—has enabled more accurate ...
Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both amyloid and tau pathology in clinical settings, but their performance in heterogeneous community-based populations is unclear. We examined P-tau181 and P-tau217 (n = 1,329, aged 30–98 years), in...
Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease. Brain Commun. 2023;5(2):fcad057. Article PubMed PubMed Central Google Scholar Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers ...
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology Nicholas J. Ashton, PhD1,2,3,4; Wagner S. Brum1,5; Guglielmo Di Molfetta, MSc1; et al Andrea L. Benedet, PhD1; Burak Arslan, MD1; Erin Jonaitis, PhD6,7,8; Rebecca E. Langhough, PhD6...
This cohort study compares plasma levels of phosphorylated tau at threonine 217 with established cerebrospinal fluid and positron emission tomography
Longitudinal plasma phosphorylated-tau217 and other related biomarkers in a non-demented Alzheimer’s risk-enhanced sampleAlzheimer’s & Dementia | July 5, 2024 Du L, Langhough RE, Wilson RE, Reyes RER, Hermann BP, Jonaitis EM, Betthauser TJ, C...
Plasma measures of phosphorylated tau at Thr181 (p-tau181), Thr217 (p-tau217) and Thr231 (p-tau231) have high diagnostic accuracy in differentiating AD from other neurodegenerative disorders in clinical studies1,2,3, which are validated by postmortem neuropathological studies1,2,4. In some...
many people with suspected cognitive impairment due to AD do not receive a biomarker-supported diagnosis. Blood biomarkers have the capacity to help expand access to AD diagnostics worldwide. One such promising biomarker is plasma phosphorylated tau (p-tau), which has demonstrated specificity to AD...